About US
Contact us
-
AstraZeneca's Brilinta looks for label boost with trial win, priority review in stroke patientsBritish drugmaker AstraZeneca has placed a lot of faith—and money—in its wide-ranging R&D program for aging blood thinner Brilinta in hopes of major label expansions. So far, those results have b2020/7/17
-
Little-known Chinese firm builds $79M COVID-19 vaccine plant, eyes production next yearNo animal data, no wordon the timeline for a clinical trial, yet one little-known Chinese company is already building a multimillion-dollar facility for a COVID-19 vaccine candidate. On Saturday, Chi2020/7/16
-
Moderna has started turning out COVID-19 vaccine doses for quick shipment if approved: CEOModerna and its partners in the federal government are just now gearing up for a late-stage COVID-19 vaccine trial set to launch later this month, but at the same time, the mRNA biotech is prepping a2020/7/16
-
Gilead's remdesivir rescued from 'scrapheap' by taxpayers, who deserve a better price: lawmakerGilead Science’s remdesivir is on the very short list of drugs that have posted positive data in COVID-19, but now one U.S. lawmaker argues the company priced the medicine too high. Taxpayers spent n2020/7/15
-
Merck KGaA's manufacturing group could see billions from COVID-19 work: analystCOVID-19 vaccines are moving forward at record speeds, but market watchers have cautioned about the looming manufacturing challenges.Merck KGaA, with its manufacturing services outfit,could see billi2020/7/15
-
J&J's Tremfya grabs psoriatic arthritis nod, setting up a battle with Cosentyx, Taltz and moreJohnson & Johnson is battling giants in the immunology field with itsIL-23 inhibitorTremfya. With other next-gen drugs already crowding the market, J&J now has the FDA's nod to take Tremfya i2020/7/14
-
Warp Speed initiative aims for COVID-19 vaccine production within 6 weeks: ReutersThe U.S. governmenthas dumped billionsinto COVID-19 vaccine developmentand manufacturing as part of its Warp Speed initiative. Now, withvaccine makers moving rapidlytoward approval, the administratio2020/7/14
-
Amgen doubles down on BeiGene investment as Chinese biotech aims to raise $2.1BIn an eye-catching transpacific collaboration last year, Amgen poured out $2.7 billion to tap into BeiGene’s commercial and R&D expertise in China. But what if an additional equity raise diluted2020/7/13
-
Roche's Tecentriq-Avastin pairing fails to keep ovarian cancer at bayImmune checkpoint inhibitors have gained a foothold in several tumor types, but not so much in ovarian cancer. Now, an early attempt by Roche to change that situation has failed. Adding PD-L1 inhibit2020/7/13
-
Moderna inks fill-finish pact with Spain's Rovi for 'hundreds of millions' of COVID-19 shot dosesModerna is on a steady marchto market with its mRNA-based COVID-19 vaccine, and the company is snapping up manufacturing capacity along the way. After inking onefill-finish deal with major CDMO Catal2020/7/10